Gibt es heute wieder eine 100%-Aktie? - 500 Beiträge pro Seite

[MrTipp]

Was meint Ihr?

[derdieschnautzelangsamvollhat]

100 nicht, aber vielleicht 10 oder20 %.

926501
508560

[juxifuxi]

Nicht nur eine - ALLE !!

[Hyper03]

Keine 100 % aber einiges sollte schon gehen.

PLANTATION, Fla., Aug. 4 /PRNewswire-FirstCall/ -- Viragen, Inc. today announced that the Company is scheduled to appear as a featured guest on Biotech Today, a New Media Internet radio show carried by World Talk Radio. The program will air live on Wednesday, August 6 from 4:00 p.m. to 5:00 p.m. (Eastern Daylight Time). The live and archived broadcast can be accessed at the following Internet link: http://www.viragen.com

Viragen has been invited on the program to discuss its collaboration with Roslin Institute (Scotland) to develop Avian Transgenic Technology as a biomanufacturing alternative to costly and relatively inefficient bioreactor technologies (Fermentation/Cell culture techniques). The goal of the project is to turn the common chicken into a highly efficient and cost-effective pharmaceutical producer for the large-scale production of recombinant protein- based drugs, such as monoclonal antibodies for the treatment of cancer.

Guests scheduled to appear on the program include: * Robert C. Salisbury, Viragen``s President and CEO. * Dr. Douglas Lind, a Viragen Board Member and former Senior Biotechnology Equity Analyst for Morgan Stanley. * Dr. Helen Sang, Roslin``s Senior Avian Molecular Biologist and Lead Scientist for the Avian Transgenic Project. Dr. Sang is one of the world``s foremost authorities on avian research and the creator of the world``s first transgenic rooster by a non-viral method. Roslin Institute is one of the world``s leading centers for research on farm and other animals and is internationally renowned for their creation of "Dolly the Sheep". About Avian Transgenic Technology

Viragen holds the worldwide exclusive license to commercialize Avian Transgenic Technology as granted by Roslin Institute. This project is designed to substitute chicken eggs for expensive bioreactor vessels presently used in the manufacture of protein-based drugs. Upon the successful completion of this project, flocks of specially produced transgenic chickens would lay virtually unlimited numbers of eggs which would have significant amounts of the target drug in the egg whites. The proportion of protein drugs, including monoclonal antibodies, under development is forecast to be expanding rapidly and manufacturing constraints, including lack of adequate facilities, have been recognized.

About Viragen, Inc.

Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon, monoclonal antibodies, peptide drugs and therapeutic vaccines. Viragen``s strategy also includes the development of Avian Transgenic Technology for the large-scale, cost-effective manufacturing of its portfolio of recombinant protein-based drugs, as well as offering Contract Manufacturing for the biopharmaceutical industry.

Viragen is publicly traded on the American Stock Exchange (VRA). Viragen``s majority owned subsidiary, Viragen International, Inc., is publicly traded on the Over-The-Counter Bulletin Board (VGNI). Viragen``s key partners and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, National Institutes of Health, Cancer Research UK, University of Nottingham (U.K.), University of Miami, America``s Blood Centers and the German Red Cross.

Viragen, Inc. Corporate Contact: Douglas Calder, Director of Communications Phone: [phone]; Fax: [phone] E-mail: [e-mail]

The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "expect", "potential", "suggests", "may", "will", "should", "could" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management``s expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company``s ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. Guests scheduled to appear on the program "Biotech Today" are potentially subject to be replaced, rescheduled or canceled due to unforeseen conflicts.

Photo: http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b AP Archive: http://photoarchive.ap.org/ PRN Photo Desk, 888-776-6555 or 212-782-2840 Viragen, Inc.

© PR Newswire

[Zimtzicke]

@ schnautzevoll




..


die hier, die Du im Tief shorten wolltest..

[Wolframit]

Denke mit dem Kauf eines Call OS auf Schwarz Pharma dürften heut auch locker 30-40 % drin seien

[derdieschnautzelangsamvollhat]

@ZZ,

Hab ich doch nur wegen Dir gepostet, damit Du billig einsammeln kannst!
So bin ich eben, ein wahrer Menschenfreund!!

[Wolframit]

Zufällig jemand ein OS auf Schwarz Pharma gekauft?

[Gnuechtel]

YEEEEEES

Call 771506 bis jetzt 22%